Organization
Concert Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Concert Pharmaceuticals, Inc.
... Study Results of ORKAMBI ProQR Therapeutics Announces Positive Proof-of-Concept Study for QR-010 Concert Pharmaceuticals Presents Positive Food Effect Results for CTP-656 Vertex Pharmaceuticals Initiates Phase ...
... LEXINGTON - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018. ...
... LEXINGTON - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter ...
... participate in our trial,' stated James Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. The Phase 2a trial is a double-blind, randomized, placebo-controlled, sequential dose ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 ...
... Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of ...
... free research to the investment community. Today we are offering reports on CNCE, CTRV, CRBP, and CORT which can be accessed for free by signing ...
... Promet's exercising of the exclusive option to license in CTP-499 from Concert Pharmaceuticals, Inc. CTP-499 is an analog of an active metabolite of an approved ...
Subscribe now for full coverage on Concert Pharmaceuticals, Inc.
Start My Free Trial